MarketCapExport financials
Sorrento Therapeutics (SRNE)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Sorrento Therapeutics Income Statement 2022-2006 | SRNE
Brief overview of financial results at Sorrento Therapeutics
This overview is based on financial performance over the past five years. Revenue reported by Sorrento Therapeutics was 20.4 million dollars at the beginning of the period and 62.8 million dollars at the end. The total change was +207.9%, with a CAGR of approximately 25.2%. Revenue growth reflects a pronounced phase of business expansion.
The operating result measured by EBITDA moved from $32.5 million to −$491 million, or −1612.2%. The operating result developed less favorably than sales. EBITDA margin moved from 159.1% to −781.5%. The business retained less EBITDA from each unit of revenue.
The final result was 9.1 million dollars initially and −573 million dollars in the final year. The move from profit to loss indicates a material deterioration in final efficiency.
Conclusion
The indicators point to a weaker financial profile. The constructive conclusion rests on sales growth. The weaker side of the profile includes declining net profitability, a narrow EBITDA buffer and a declining EBITDA margin. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Sorrento Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
- | 746 M | 2.22 B | 288 M | 215 M | 694 M | 262 M | 223 M | 345 M | 173 M | 57 K | 2.56 B | - | - | - | - | - |
Shares |
419 M | 295 M | 230 M | 133 M | 106 M | 69.7 M | 50.4 M | 36.9 M | 26.7 M | 15 M | 11.4 K | 262 M | 251 M | 11.1 M | - | - | - |
Historical Prices |
- | 2.53 | 9.67 | 2.17 | 2.03 | 9.95 | 5.2 | 6.04 | 12.9 | 11.5 | 5 | 9.75 | - | - | 25 | 70 | 107 K |
Net Income |
-573 M | -428 M | -298 M | -292 M | -204 M | 9.13 M | -60.9 M | -45.8 M | -34.7 M | -21.9 M | -4.84 M | -3.24 M | -1.81 M | -942 K | -25.7 K | -16.3 K | -75.8 K |
Revenue |
62.8 M | 52.9 M | 40 M | 13 M | 6.93 M | 20.4 M | 4.02 M | 4.59 M | 3.82 M | 460 K | 584 K | 529 K | 683 K | - | - | - | - |
Cost of Revenue |
- | - | - | - | 7.06 M | 3.94 M | 811 K | 1.95 M | 2.04 M | 4 K | - | - | - | - | - | - | - |
Gross Profit |
- | - | 30 M | 19.2 M | 14.1 M | 148 M | 7.34 M | 2.64 M | 1.78 M | 456 K | - | 529 K | - | - | - | - | - |
Operating Income |
-504 M | -401 M | -245 M | -259 M | -150 M | 25.3 M | -96.8 M | -74 M | -34.7 M | -21.7 M | -4.85 M | -3.24 M | -1.81 M | - | - | - | - |
Interest Expense |
8.57 M | 10.2 M | 20.2 M | 35 M | 57.6 M | 4.98 M | 1.61 M | 1.65 M | 1.63 M | 253 K | - | - | - | - | - | - | - |
EBITDA |
-491 M | -389 M | -234 M | -248 M | -141 M | 32.5 M | -93.9 M | -71.6 M | -31.6 M | -20.4 M | -4.56 M | -3.08 M | -1.79 M | - | - | - | - |
Operating Expenses |
- | - | 232 M | 214 M | 144 M | 96.5 M | 67.2 M | 52.6 M | 36.3 M | 16.1 M | 5.44 M | 3.77 M | 2.49 M | - | - | - | - |
General and Administrative Expenses |
182 M | 197 M | 116 M | 104 M | 63.6 M | 38.3 M | 24.2 M | 20.1 M | 9.99 M | 6.32 M | 1.61 M | 1.2 M | 1.1 M | - | - | - | - |
All numbers in USD currency
Quarterly Income Statement Sorrento Therapeutics
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
551 M | 543 M | 523 M | 452 M | 403 M | 337 M | 315 M | 299 M | 290 M | 281 M | 268 M | 251 M | 217 M | 183 M | 155 M | 131 M | 123 M | 122 M | 122 M | 117 M | 101 M | 84.9 M | 80.5 M | 76.9 K | 70.3 K | 50.9 K | 58.6 M | 66.2 K | 46.5 M | 38 M | 37.8 M | 37.3 M | 36.3 K | 36.2 K | 29.6 M | 28.5 M | 25.3 M | 23.1 M | 23 M | 14.1 M | 13.4 M | 308 M | 12 M | 300 M | 300 M | 262 M | 262 M | 250 M | 250 M | 262 M |
Net Income |
-95.2 M | -140 M | - | -89.6 M | -219 M | -40.8 M | -144 M | -120 M | -167 M | 2.51 M | -71.5 M | -84 M | -77.7 M | -65.2 M | -62.8 M | -64.4 M | -56.8 M | -108 M | -49.8 M | -47.3 M | -73.9 M | -32.6 M | 48.4 M | -2.06 M | -14.2 M | -23.1 M | -17.9 M | 14.4 M | -44.9 M | -18.4 M | -26.6 M | -939 K | -11 M | -10.4 M | -8.5 M | -7.6 M | -8.45 M | -10.1 M | - | -3.36 M | -4.74 M | -2.52 M | - | -1.24 M | -943 K | -906 K | - | -702 K | -1.09 M | -684 K |
Revenue |
15 M | 16.3 M | - | 17.4 M | 11.5 M | 18.4 M | 13.1 M | 12.1 M | 13.5 M | 14.3 M | 11.5 M | 11.8 M | 9.01 M | 7.72 M | 13 M | 5.78 M | 6.48 M | 6.14 M | 6.93 M | 4.1 M | 3.91 M | 6.25 M | 20.4 M | 122 M | 4.66 M | 4.87 M | 4.02 M | 2.24 M | 902 K | 988 K | 1.34 M | 1.1 M | 1.17 M | 977 K | 798 K | 1.28 M | 775 K | 976 K | - | 83.8 K | 142 K | 134 K | - | 135 K | 217 K | 110 K | - | 91.8 K | 74.2 K | 235 K |
Cost of Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.28 M | 2.31 M | - | 2.18 M | 1.23 M | 1.31 M | - | 1.08 M | 816 K | 1.06 M | - | 418 K | 295 K | 359 K | - | 604 K | 314 K | 509 K | - | 527 K | 510 K | 563 K | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-77.2 M | -106 M | - | -109 M | -118 M | -107 M | - | -101 M | -101 M | -84.9 M | - | -83.1 M | -47.7 M | -43.2 M | - | -53.3 M | -50.4 M | -123 M | - | -47.9 M | -28.4 M | -32.5 M | - | 96.9 M | -13.5 M | -23.3 M | - | -13.8 M | -46.4 M | -24.8 M | - | -35.6 M | -10.5 M | -10.2 M | - | -7.13 M | -7.99 M | -9.87 M | - | -3.31 M | -4.72 M | -2.51 M | - | -1.24 M | -945 K | -908 K | - | -704 K | -1.09 M | -686 K |
Interest Expense |
2.67 M | 1.13 M | - | 792 K | 2.31 M | 3.25 M | - | 2.9 M | 2.02 M | 2.37 M | - | 2.56 M | 8.3 M | 6.82 M | - | 9.46 M | 9.52 M | 9.08 M | - | 2.68 M | 45 M | 1.05 M | - | 1.21 M | 1.2 M | 1.61 M | - | 236 K | 273 K | 307 K | - | 396 K | 442 K | 439 K | - | 476 K | 468 K | 223 K | - | 51.3 K | 21.8 K | 9.93 K | - | - | - | - | - | - | - | - |
EBITDA |
-70 M | -103 M | - | -99.6 M | -112 M | -104 M | - | -91.8 M | -94.5 M | -82 M | - | -74.3 M | -42.1 M | -40.1 M | - | -45 M | -44.4 M | -120 M | - | -41.7 M | -24.4 M | -30.5 M | - | 102 M | -10.3 M | -21.9 M | - | -12.5 M | -45.3 M | -24.2 M | - | -33.8 M | -9.11 M | -9.35 M | - | -4.76 M | -6.42 M | -9.1 M | - | -2.67 M | -4.39 M | -2.41 M | - | -1.03 M | -813 K | -845 K | - | -600 K | -1.03 M | -673 K |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.39 M | 4.86 M | 2.65 M | - | 1.38 M | 1.16 M | 1.02 M | - | 795 K | 1.16 M | 921 K |
General and Administrative Expenses |
48.9 M | 55 M | - | 50.2 M | 48.1 M | 44.3 M | - | 48.5 M | 50.4 M | 43.4 M | - | 24.3 M | 24.5 M | 26.3 M | - | 25.2 M | 27.8 M | 25.1 M | - | 20.1 M | 11 M | 9.96 M | - | 10.2 M | 9.09 M | 11.9 M | - | 5.27 M | 4.22 M | 4.5 M | - | 4.71 M | 3.07 M | 2.22 M | - | 1.85 M | 2.36 M | 3.38 M | - | 1.11 M | 1.51 M | 1.25 M | - | 427 K | 245 K | 219 K | - | 159 K | 527 K | 333 K |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Sorrento Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Schweiz
USA
Israel
China
Canada
Britain
Russia
